TRAIL受体DR4、DR5、DcR1在结肠癌中的表达及意义

目的 探讨肿瘤坏死因子相关凋亡导配体(TRAIL)受体DR4、DR5、DcR1在结肠癌中的表达及临床意义,为TRAIL的抗肿瘤作用提供实验依据.方法 采用免疫组化SP法检测35例结肠癌和14例正常结肠黏膜组织中DR4、DR5、DcR1表达水平.结果 35例结肠癌组织中DR5的阳性表达率为27/35(77.14%),DR...

Expression and significance of TRAIL-R DR4, DR5, DcR1 in colorectal carcinoma

Objective To investigate the expression and significance of TRAIL(TNF-related apoptosis inducing ligand),DR4,DR5,DcR1 in colorectal carcinoma.Methods The immunohistochemical technique(SP) was used to detect the expression of TRAIL-R,DR4,DR5,DcR1 in 35 cases of colorectal carcinoma and 14 cases of normal colorectal mucosa.Results The positive expression rate of DR5 in colorectal carcinoma was 27/35(77.14%),DR4 was 19/35(54.28%),and the positive expression rate of DR5 in colorectal carcinoma was significantly higher than that [4/14(28.57%)] in normal colorectal mucosa(P<0.05),so was the positive expression rate of DR4(P<0.05).The expression of DcR1 in normal colorectal mucosa was 100%,which was significantly higher than that [13/35(37.14%)] in colorectal carcinoma(P<0.05).Conclusion The high expression of DR4,DR5 in colorectal carcinoma provides theoretical feasibility for TRAIL to treat colorectal carcinoma.The DR5 may play an important role in the apoptosis pathway induced by TRAIL.The expression of DcR1 in colorectal carcinoma may result in the tolerance of cell apoptosis induced by TRAIL.